Nevertheless, CP-456773/MCC950 remains a prevalent NLRP3 inhibitor in both in vitro and in vivo studies of numerous diseases, including diabetes, atherosclerosis, myocardial infarction, neurodegenerative diseases, and myeloid malignancies [17, 52–57]. Here, NLRP3 is linked to atherosclerosis.